Search company, investor...



Unattributed | Alive

Total Raised


Last Raised

$1.15M | 9 yrs ago

About ioGenetics

ioGenetics combines immunoinformatics and recombinant protein engineering for the design, discovery, and early development of biotherapeutics, vaccines and diagnostics. uTOPE immunoinformatics analysis can assess antigenicity of biopharmaceuticals, and assist optimization and patient stratification. Applications include products for diagnosis or management of infectious diseases, allergy, autoimmunity, and cancer.

Headquarters Location

3591 Anderson Street Suite 218

Madison, Wisconsin, 53704,

United States


Missing: ioGenetics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ioGenetics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ioGenetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ioGenetics is included in 2 Expert Collections, including Health Monitoring & Diagnostics.


Health Monitoring & Diagnostics

2,623 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

ioGenetics Patents

ioGenetics has filed 18 patents.

The 3 most popular patent topics include:

  • Immune system
  • Immunology
  • Clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Flaviviruses, Animal viral diseases, Zoonoses, Hemorrhagic fevers, Viral diseases


Application Date


Grant Date



Related Topics

Flaviviruses, Animal viral diseases, Zoonoses, Hemorrhagic fevers, Viral diseases



Latest ioGenetics News

Cryptosporidiosis Pipeline Review: H1 2018 - Covering Key Players AbbVie, ioGenetics, Novartis and Romark Laboratories -

Jun 7, 2018

June 07, 2018 06:09 AM Eastern Daylight Time This latest pipeline guide provides comprehensive information on the therapeutics under development for Cryptosporidiosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The pipeline guide also reviews key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical stages are 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Companies Mentioned Products under Development by Universities/Institutes Cryptosporidiosis - Therapeutics Assessment Assessment by Route of Administration Assessment by Molecule Type AbbVie Inc

ioGenetics Frequently Asked Questions (FAQ)

  • Where is ioGenetics's headquarters?

    ioGenetics's headquarters is located at 3591 Anderson Street, Madison.

  • What is ioGenetics's latest funding round?

    ioGenetics's latest funding round is Unattributed.

  • How much did ioGenetics raise?

    ioGenetics raised a total of $1.35M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.